Nifedipine and Vascular Smooth Muscle Cells in Atherogenesis: In Vivo and In Vitro Studies
Several calcium antagonists have been reported to be effective antiatherogenic agents . Among the calcium antagonists, nifedipine is the foremost and perhaps the most widely studied drug. In experimental animals  as well as in humans , nifedipine has been found to prevent the development of newly formed lesions and/or the progression of preexisting atherornas. Some conflicting findings regarding the efficacy of nifedipine and other calcium antagonists [1,4] in preventing experimental atherosclerosis are likely to be due to differences in the experimental conditions, the species or breed of animals used, or the method employed for assessing atherosclerosis. On the whole, the results of the majority of studies are consistent with the assumption of an appreciable antiatherogenic effect of at least three calcium antagonists, namely nifedipine, verapamil, and isradipine , and indicate that calcium antagonists promise well for clinical use in this field also. Never- theless, the mechanism or mechanisms by which calcium antagonists may exert their antiatherogenic effect remains poorly understood. Since it is presently well accepted that vascular smooth muscle cells (SMC) are the major contributor to the formation of atherosclerotic plaque , we have studied SMC composition in the intimai thickening of hypercholesterolemic rabbits treated with nifedipine. A panel of monoclonal antimyosin antibodies was used to study SMC differentiation during atherogenesis and nifedipine treatment. These antibodies were directed against smooth-muscle or nonmuscie myosin isoforms . This approach allowed the identification of different SMC populations in the aortic wall and enabled us to define their modulation during atherogenesis. We also studied the influence of nifedipine on growth rate and incorporation of [3H]thymidine in SMC cultured from the aortic media.
KeywordsCholesterol Formalin Turkey Paraffin Verapamil
Unable to display preview. Download preview PDF.
- 1.Overturf M, Smith S (1989) Are calcium antagonists effective inhibitors of atherogenesis? In: Dal Palù C, Ross R (eds) Hypertension and atherosclerosis. Excerpta Medica, Amsterdam, pp 98–106Google Scholar
- 7.Pauletto P, Scannapieco G, Vescovo G, Pessina AC, Dal Palù C (1989) Prevention of aortic hypertrophy in spontaneously hypertensive turkeys. J Hypertens 7 [Suppl 6]: S246Google Scholar
- 8.Pauletto P, Sartore S, Scannapieco G, Borrione AC, Zanellato AMC, Pessina AC, Dal Palù C (1989) Immunocytochemical analysis of myosin isoform distribution in the atherosclerotic lesions of cholesterol-fed rabbits. In: Dal Palù C, Ross R (eds) Hypertension and atherosclerosis. Excerpta Medica, Amsterdam, p 107Google Scholar
- 9.Zanellato AMC, Borrione AC, Tonello M, Scannapieco G, Pauletto P, Dal Palù C, Sartore S (1988) Myosin heavy chain isoforms in bovine smooth muscle and in smooth muscle cells grown in vitro. A monoclonal antibody study. In: Carraro U (ed) Sarcomeric and non-sarcomeric muscles: basic and applied research prospects for the 90s. Unipress Padova, Padua, p 687Google Scholar
- 10.Scannapieco G, Pauletto P, Pagnan A, Mattiello A, Biffanti S, Joni G, Dal Palù C (1988) Lipoprotein binding to cultured aortic smooth muscle cells from normotensive and hypertensive rats. J Hypertens 6 [Suppl 4]: S269Google Scholar
- 13.Moolenaar WH, Tertoolen LGJ, de Laat SW (1989) Growth factors immediately raise cytoplasmic free calcium in human fibroblasts. J Biol Chem 259: 8066Google Scholar